DHEA replacement in women with adrenal insufficiency--pharmacokinetics, bioconversion and clinical effects on well-being, sexuality and cognition - PubMed

Clinical Trial

DHEA replacement in women with adrenal insufficiency--pharmacokinetics, bioconversion and clinical effects on well-being, sexuality and cognition

W Arlt et al. Endocr Res. 2000 Nov.

Abstract

Standard replacement for adrenal insufficiency (AI) consists of glucocorticoids and mineralocorticoids while DHEA deficiency is routinely ignored. Thus, AI represents the ideal pathophysiological model of isolated DHEA deficiency. We investigated the effects of DHEA replacement in 24 women with primary and secondary AI employing a double blind, placebo-controlled, randomized crossover design. A DHEA dose of 50 mg/d was chosen based on preceding single-dose pharmacokinetics and bioconversion studies. Each patient received four months of treatment with DHEA and four months placebo, with a one-month washout period. Measurements included serum steroid hormones, somatotropic parameters and psychometric assessment of well-being, mood, cognition and sexuality. Treatment with DHEA raised the initially low serum concentrations of DHEA, DHEAS, androstenedione, and testosterone into the normal range. DHEA induced a slight increase in serum IGF-I, but only in patients with primary AI, suggesting a growth hormone-mediated effect. DHEA treatment significantly improved overall wellbeing as well as scores for depression, anxiety, and their physical correlates. Furthermore, DHEA significantly increased both sexual interest and the level of satisfaction with sex. DHEA replacement had no influence on the cognitive performance, which was already on a high level at baseline. In conclusion, DHEA replacement improves well-being and sexuality in women with adrenal insufficiency. If this is due to a direct effect of DHEA on the brain, an indirect effect via increased androgen synthesis, or both, remains to be elucidated. Long-term studies in patients of both sexes are needed to further define the role of DHEA in standard replacement for adrenal insufficiency.

Similar articles

• Dehydroepiandrosterone replacement in women with adrenal insufficiency.

  Arlt W, Callies F, van Vlijmen JC, Koehler I, Reincke M, Bidlingmaier M, Huebler D, Oettel M, Ernst M, Schulte HM, Allolio B. Arlt W, et al. N Engl J Med. 1999 Sep 30;341(14):1013-20. doi: 10.1056/NEJM199909303411401. N Engl J Med. 1999. PMID: 10502590 Clinical Trial.

• Dehydroepiandrosterone substitution in female adrenal failure: no impact on endothelial function and cardiovascular parameters despite normalization of androgen status.

  Christiansen JJ, Andersen NH, Sørensen KE, Pedersen EM, Bennett P, Andersen M, Christiansen JS, Jørgensen JO, Gravholt CH. Christiansen JJ, et al. Clin Endocrinol (Oxf). 2007 Mar;66(3):426-33. doi: 10.1111/j.1365-2265.2007.02750.x. Clin Endocrinol (Oxf). 2007. PMID: 17302879 Clinical Trial.

• Effects of dehydroepiandrosterone (DHEA) supplementation on hormonal, metabolic and behavioral status in patients with hypoadrenalism.

  Libè R, Barbetta L, Dall'Asta C, Salvaggio F, Gala C, Beck-Peccoz P, Ambrosi B. Libè R, et al. J Endocrinol Invest. 2004 Sep;27(8):736-41. doi: 10.1007/BF03347515. J Endocrinol Invest. 2004. PMID: 15636426 Clinical Trial.

• Is DHEA replacement beneficial in chronic adrenal failure?

  Lang K, Burger-Stritt S, Hahner S. Lang K, et al. Best Pract Res Clin Endocrinol Metab. 2015 Jan;29(1):25-32. doi: 10.1016/j.beem.2014.09.007. Epub 2014 Oct 2. Best Pract Res Clin Endocrinol Metab. 2015. PMID: 25617170 Review.

• Androgen therapy with dehydroepiandrosterone.

  Buvat J. Buvat J. World J Urol. 2003 Nov;21(5):346-55. doi: 10.1007/s00345-003-0367-7. Epub 2003 Oct 10. World J Urol. 2003. PMID: 14551720 Review.

Cited by

• Developmental changes in the endocrine stress response in orangutans (Pongo pygmaeus).

  Takeshita RSC, Mendonça RS, Bercovitch FB, Huffman MA. Takeshita RSC, et al. J Comp Physiol B. 2019 Dec;189(6):659-672. doi: 10.1007/s00360-019-01235-7. Epub 2019 Sep 23. J Comp Physiol B. 2019. PMID: 31549180

• Transformations of DHEA and its metabolites by rat liver.

  Lardy H, Marwah A, Marwah P. Lardy H, et al. Lipids. 2002 Dec;37(12):1187-91. doi: 10.1007/s11745-002-1019-7. Lipids. 2002. PMID: 12617473

• Androgen deficiency in hypopituitary women: its consequences and management.

  Esposito D, Tivesten Å, Olivius C, Ragnarsson O, Johannsson G. Esposito D, et al. Rev Endocr Metab Disord. 2024 Jun;25(3):479-488. doi: 10.1007/s11154-024-09873-1. Epub 2024 Jan 19. Rev Endocr Metab Disord. 2024. PMID: 38240912 Free PMC article. Review.

• Circulating dehydroepiandrosterone sulfate concentrations during the menopausal transition.

  Crawford S, Santoro N, Laughlin GA, Sowers MF, McConnell D, Sutton-Tyrrell K, Weiss G, Vuga M, Randolph J, Lasley B. Crawford S, et al. J Clin Endocrinol Metab. 2009 Aug;94(8):2945-51. doi: 10.1210/jc.2009-0386. Epub 2009 May 26. J Clin Endocrinol Metab. 2009. PMID: 19470626 Free PMC article.

• Studies on homocysteine and dehydroepiandrosterone sulphate plasma levels in Alzheimer's disease patients and in Parkinson's disease patients.

  Genedani S, Rasio G, Cortelli P, Antonelli F, Guidolin D, Galantucci M, Fuxe K, Agnati LF. Genedani S, et al. Neurotox Res. 2004;6(4):327-32. doi: 10.1007/BF03033443. Neurotox Res. 2004. PMID: 15545016

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon

• Medical

  • MedlinePlus Health Information